Early Clinical
Overview
Invicro’s early clinical imaging services deliver decision-making data for drug development teams in Phases 0, I and II. We have many years of pharma industry experience, and this understanding of the drug development process helps us design and execute imaging studies so that the resultant data reduces risk in later phases of development. We own and operate clinics in London, UK and New Haven, CT allowing us to execute studies in both Europe and North America as required. Our focus is to provide high-quality, quantitative data to:
- Detect and measure expression of tissue biomarkers
- Confirm drug penetration in the target tissue of interest
- Measure of drug engagement of the desired molecular target
- Establish evidence of modification of target activity following drug interaction
- Evaluate early evidence of treatment response
Modalities
- SPECT
- PET
- PET/CT
- PET/MRI
- MRI
- CT
- Ultrasound
- Additional Modalities Available
Thought Leadership Content
Case Studies
Rhesus Teeth Segmentation by Use of Multi-Atlas Library
Estimating Posterior Lumbar Fusion Integrity Using Conductivity Analysis
Antigen Density Estimation – Clinical PET/CT Protocol Design for a First-In-Human Diagnostic Peptide
Lipid Quantification Tool Development Using Multi-Echo MRI
Webinars
Translating Radiolabeled Biologics – Strategies for Successful IND Submission
Segmentation of Lesions in Whole-Body PET/CT Using Deep Learning
Utilizing Imaging Agent Biomarkers for Improved Patient Management – Challenges and Successes
PSMA: Imaging Biomarker Development
Molecular Imaging in Neurodegenerative Disorders: Developing a Translational Toolbox
Wherefore art Tau? Developing Methods for the Qualitative Interpretation of Tau PET
The IQ Analytics Platform: Amyloid-IQ, Tau-IQ and Dat-IQ
Advanced Imaging Biomarkers in Alzheimer’s Disease